Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 |
| clinicaltrials |
| NCT02775435 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | completed | Phase 3 | 559 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 8, 2024 | clinicaltrials |
| NCT03875092 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | completed | Phase 3 | 125 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06607796 | Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | recruiting | Phase 3 | 180 | Zhou ChengzhiOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT00365105 | Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer | completed | Phase 3 | 261 | Radiation Therapy Oncology GroupNETWORK | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02578680 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | completed | Phase 3 | 616 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT02864394 | Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | completed | Phase 3 | 425 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT04776083 | Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients | completed | Phase 3 | 75 | Menoufia UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01996098 | Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation(ICTAN) | terminated | Phase 3 | 251 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06581380 | JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 394 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT06523673 | Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer(OPPRESS) | recruiting | Phase 3 | 104 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06569420 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | active not recruiting | Phase 3 | 275 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT05341583 | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | unknown | Phase 3 | 202 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05654454 | A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | recruiting | Phase 3 | 620 | Mabscale, LLCINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT03866499 | A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients | unknown | Phase 3 | 369 | Beta Pharma ShanghaiINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05055908 | Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors(BECOME) | recruiting | Phase 3 | 12,000 | Hunan Province Tumor HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06128694 | Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients | unknown | Phase 3 | 108 | Kalbe International Pte. LtdINDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06526624 | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 406 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jul 30, 2024 | clinicaltrials |
| NCT04194203 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | completed | Phase 3 | 305 | Hoffmann-La RocheINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT03195491 | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia(CheckMate870) | completed | Phase 3 | 400 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 18, 2024 | clinicaltrials |
| NCT04028050 | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(MAURIS) | completed | Phase 3 | 155 | Hoffmann-La RocheINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04902885 | Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients | completed | Phase 3 | 95 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06485557 | A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC | unknown | Phase 3 | 90 | Tang-Du HospitalOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT04233476 | 99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer(TRIIL) | completed | Phase 3 | 409 | RDO Pharm.INDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 7 | Jun 26, 2024 | clinicaltrials |
| NCT03743064 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 8 | Jun 26, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04642469 | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.(MERMAID-2) | completed | Phase 3 | 30 | AstraZenecaINDUSTRY | 25 | Jun 25, 2024 | clinicaltrials |
| NCT04143607 | ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 337 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT02974426 | To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | terminated | Phase 3 | 132 | Shanghai Chest HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03950674 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | completed | Phase 3 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 10, 2024 | clinicaltrials |
| NCT04322617 | Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer(ATHENA) | recruiting | Phase 2 / Phase 3 | 1,200 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441344 | Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell(SCLC) | not yet recruiting | Phase 3 | 136 | Taizhou HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT05717803 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | recruiting | Phase 3 | 307 | Fudan UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT03632603 | PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study(PARAT) | unknown | Phase 3 | 1,184 | University of AarhusOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03117049 | Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | completed | Phase 3 | 550 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 6, 2024 | clinicaltrials |
| NCT05493501 | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | terminated | Phase 3 | 8 | EQRx International, Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT06300177 | D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure | recruiting | Phase 3 | 522 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06380348 | JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations | not yet recruiting | Phase 3 | 398 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Apr 23, 2024 | clinicaltrials |
| NCT04909684 | Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC(DEDICATION-1) | unknown | Phase 3 | 750 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03866980 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | terminated | Phase 3 | 164 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03866993 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 350 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT00310232 | Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) | terminated | Phase 3 | 70 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03699956 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer(REPLATINUM) | terminated | Phase 3 | 18 | EpicentRx, Inc.INDUSTRY | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06323148 | Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) | not yet recruiting | Phase 3 | 226 | Fudan UniversityOTHER | 0 | Mar 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2024source: clinicaltrials